News & Media

Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit

NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference

NextRNA Therapeutics names Dominique Verhelle as CEO and expands leadership team

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with Rory Johnson, PhD

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with Susan Carpenter, PhD

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with John Mattick, PhD